Our immune system is built to find and destroy outside threats, but sometimes that vigilance turns against us. Scientists have found that premature tissue aging is often driven less by DNA damage itself than by an overreaction: the body mistaking pieces of its own cells for a dangerous viral invasion.
How a recognition error starts
Normally, DNA repair machinery runs continuously inside every cell. In rare genetic disorders such as Bloom syndrome or ataxia-telangiectasia, or under severe stress, that system fails.
Broken DNA fragments leak from the nucleus into the cytoplasm. There they meet a molecular sensor called cGAS. Its evolutionary job is to spot viral DNA and raise the alarm. But cGAS cannot tell foreign DNA from the cell's own: seeing floating fragments, it treats the cell as infected and triggers a strong sterile inflammatory response.
A double hit on the body
An international team at the Hebrew University of Jerusalem, led by Dr. Marva Bergman and Professor Itamar Harel, found that the cGAS sensor harms the cell in two ways:
- Chronic inflammation: a constant "viral attack" signal wears tissues down, inflames the nervous system, and drives premature cell death.
- Blocked repair: cGAS can move back into the nucleus and directly interfere with remaining DNA repair, worsening genomic chaos.
For decades it was assumed cells fail under the weight of accumulated DNA breaks. The new work suggests the body could cope with that damage much longer if the immune sensor did not stage a destructive panic.
Quiet the alarm, and tissues recover function
To test the idea, researchers used a vertebrate model. They dialed down cGAS activity in organisms with rapid-aging syndromes and got a clear result.
Instead of merely slowing decline, they saw real recovery: inflammation fell sharply, degeneration stopped, and reproductive capacity returned in the test animals.
Tissues kept working despite DNA damage because the inflammatory reaction that was destroying them had stopped.
What this means for medicine
The finding shifts how we think about treating rare premature-aging syndromes and age-related organ decline in general.
Rather than trying to fix every microscopic DNA break, an often impossible task, doctors could focus on damping false alarm signals. The hard problem for drug makers is selective: lower cGAS hyperactivity without stripping the body of its main defense against real viral infections.
